Analysis Of Income And Expense [Abstract]

Ascelia Pharma - Filing #701899

Concept 2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
- SEK
- SEK
Material income and expense [abstract]
Research and development expense
107 574 SEK
64 764 SEK
Finance income (cost)
8 425 SEK
6 319 SEK
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
- SEK
- SEK
135,000 SEK
135,000 SEK
- SEK
135,000 SEK
- SEK
- SEK
- SEK
5,000 SEK
5,000 SEK
- SEK
5,000 SEK
- SEK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
SEK
SEK
135,000 SEK
125 768 SEK
SEK
125 768 SEK
125 903 SEK
98 697 SEK
SEK
98 702 SEK
5,000 SEK
SEK
98 702 SEK
SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.